Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Recommendation of “Reduce” from Brokerages

Simulations Plus, Inc. (NASDAQ:SLP) has been given a consensus rating of “Reduce” by the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and seven have issued a hold rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $17.25.

A number of research analysts have recently commented on the company. Weiss Ratings upgraded Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, July 10th. Craig Hallum cut Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price target on the stock. in a research note on Thursday, June 18th. William Blair downgraded Simulations Plus from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 17th. Finally, Wall Street Zen lowered Simulations Plus from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th.

Insider Buying and Selling at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 4,177 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $18.44, for a total value of $77,023.88. Following the transaction, the director directly owned 3,202,131 shares of the company’s stock, valued at approximately $59,047,295.64. This trade represents a 0.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. bought a new position in Simulations Plus in the 2nd quarter worth $25,000. Quarry LP purchased a new position in Simulations Plus during the third quarter valued at $28,000. GAMMA Investing LLC grew its holdings in Simulations Plus by 26.0% during the second quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock valued at $52,000 after purchasing an additional 585 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in Simulations Plus by 343.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company’s stock valued at $73,000 after purchasing an additional 3,084 shares during the period. Finally, Longfellow Investment Management Co. LLC purchased a new stake in Simulations Plus in the second quarter worth about $77,000. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Simulations Plus Price Performance

Shares of NASDAQ SLP opened at $18.32 on Thursday. Simulations Plus has a 1 year low of $11.09 and a 1 year high of $21.01. The company’s 50-day moving average is $17.95 and its 200 day moving average is $15.30. The stock has a market capitalization of $370.52 million, a P/E ratio of 45.80 and a beta of 1.32.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.07. The company had revenue of $21.89 million during the quarter, compared to the consensus estimate of $20.90 million. Simulations Plus had a net margin of 9.88% and a return on equity of 13.50%.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.